?
Генетические аспекты нейропсихиатрической симптоматики при болезни Паркинсона
The review presents the data on the effects of the COMT, MAO-A, MAO-B, DAT, DRD2, VMAT2, TPH2 and SNCA genes on Parkinson's disease, the effectiveness of therapy and theiraffinity to a number of mental disorders. A systematic review was conducted with 77 articles and monographs devoted to the problems of genetics, neurology and psychiatry, published in the period from 1972 to 2018. Early recognition of the disease genetic features will optimize drug therapy, predict early complications of the disease, such as: cognitive decline, affective, obsessive-compulsive, psychotic disorders, and impulse control disorder. Genetic perdition of clinical features of Parkinson's disease can be also helping in selecting and preparing patients for deep brain stimulation